Date:5/14/2012

rea RA: Post-Hoc Efficacy Palo Alto, CA Analysis of Long-Term ACQUIRE (SC) Data with AIM (IV) Data June 8, 2012, 11:45 Immunogenicity is Low M. Weinblatt AM, Poster Area and Transient with Boston, MA Intravenous Abatacept Therapy June 9, 2012, 10:45 Efficacy and Safety of R. Furie AM, Poster Area Hall Abatacept in Lupus Lake Success, NY 2.2 Nephritis June 9, 2012, 10:15 Comparative Analysis D. Wofsy AM, Poster Area of Alternative Outcome San Francisco, CA Measures for use in Lupus Nephritis Trials June 8, 2012, 11:45 In Patients with P. Emery AM, Poster Area Established RA, Leeds, United Kingdom Abatacept Efficacy is Independent of Baseline Annual Radiographic Progression Rate June 7, 2012, 11:45 A Multi-Center, T. Matsubara AM, Poster Area Double-Dummy, Kato, Japan Double-Blind Study of Subcutaneous (SC) Abatacept (ABA) Compared with Intraveneous (IV) ABA in Japanese Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate

About ORENCIA® (abatacept)

Abatacept is a selective co-stimulation modulator of T-cell activation. It is designed to prevent full T-cell activation and inhibit the release of chemicals leading to joint inflammation and destruction as observed in RA^{[i,ii,iii,iv]} and pJIA.^[1]

Abatacept is the first biologic discovered and developed in Bristol-Myers Squibb research centres and abatacept IV was first approved for adult RA in May 2007 by the European Commission. Abatacept SC is not currently licensed in the European Union.

Abatacept in combination with methotrexate (MTX) is indicated for the treatment of moderate to severe active RA in adult patients who responded inadequately to previous therapy with one or more DMARDs including MTX or a TNF-alpha inhibitor. A reduction in the progression of joint damage and improvement of physical function have been demonstrated during combination treatment with abatacept and MTX.

Abatacept, in combination with MTX, is also in
'/>"/>

SOURCE Bristol-Myers Squibb Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. BT Signs Multi-Year, Managed Services Contract with Bristol-Myers Squibb
2. Simcere and Bristol-Myers Squibb Enter Innovative Partnership to Develop Cardiovascular Compound
3. Bristol-Myers Squibb: Performance, Capabilities, Goals and Strategies in the Worldwide Pharmaceutical Market
4. GNS Healthcare Announces Collaboration With Bristol-Myers Squibb
5. Alder Biopharmaceuticals to Receive $15 Million Milestone Payment from Bristol-Myers Squibb for Initiation of Phase 2b Clinical Trial in Rheumatoid Arthritis of ALD518/BMS-945429 Antibody Therapeutic Against IL-6
6. Bristol-Myers Squibb and WuXi PharmaTech Announce Collaboration for a New Analytical and Stability Testing Facility
7. Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab
8. Bristol-Myers Squibb Sued for Denying Employees Overtime Pay
9. Bend Research Announces Extension of Drug-Discovery Enablement and Development Services Agreement With Bristol-Myers Squibb
10. Isis Earns $6 Million Milestone Payment From Bristol-Myers Squibb for BMS-PCSK9Rx
11. Top Bristol-Myers Squibb Executive Joins Patton Boggs